Drug Type Bispecific antibody |
Synonyms |
Target |
Mechanism 4-1BB inhibitors(Tumor necrosis factor receptor superfamily member 9 inhibitors), HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | CN | 03 Jun 2018 |